MYC and melanoma: In TNBC, upregulated MYC inhibits the MondoA-dependent activation of TXNIP to stimulate glycolysis [138], while in BRAF-mutant melanoma, the MYC-induced downregulation of the MondoA-TXNIP axis leads to vemurafenib resistance [139].